Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on ...

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

Journey Medical (DERM) announced that results from the Phase 1 clinical trial assessing the impact of low-dose oral minocycline, DFD-29, on skin, ...

Ivermectin became a source of debate during the COVID-19 pandemic, though it is not FDA-approved as an antiviral or for treating viruses, including COVID-19.

There is no shortage of tips on social media for how to get healthier-looking locks. Some influencers claim that applying plant extracts to your scalp and hair strands can improve hair health and ...

Several new laws take effect in Texas today that will bring change to the state’s education system, tax laws and pharmacies.

Millions of Medicare Part D enrollees will see substantial out-of-pocket savings as negotiated drug prices take effect in ...

For the first time in decades, the US Food and Drug Administration has signed off on new antibiotics to fight gonorrhea. The approvals come at a critical moment: The sexually transmitted infection is ...

A single-dose oral medication called zoliflodacin shows promise as a new treatment for antibiotic-resistant gonorrhea, ...

Ramaswamy’s latest startup, Ambros Therapeutics, launched Tuesday with plans to develop a treatment for a rare form of the ...

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...